<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pepsreview.com/articles/celltrion-four-target-obesity-drug-mouse-study</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title><![CDATA[Celltrion's Four-Target Obesity Drug Beats Triple Agonists in Mice, Human Data Still Years Away]]></news:title>
      <news:keywords>Celltrion CT-G32, quadruple agonist, obesity drug pipeline, GLP-1, retatrutide, preclinical data, IND filing, lean mass preservation</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/novo-aasld-2026-semaglutide-efruxifermin-mash-liver-data</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title><![CDATA[Novo Nordisk Brings 12 Liver Abstracts to AASLD 2026 — With the Results Still Under Wraps]]></news:title>
      <news:keywords>semaglutide MASH, AASLD 2026, efruxifermin, MASH liver disease, GLP-1 liver data, ESSENCE trial, resmetirom</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/tga-approves-first-oral-glp1-weight-loss-tablet-australia</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-03</news:publication_date>
      <news:title><![CDATA[Australia Approves Its First Oral GLP-1 Weight-Loss Tablet — and Nobody Can Buy One Yet]]></news:title>
      <news:keywords>TGA Wegovy tablet, oral semaglutide Australia, GLP-1 tablet approval, Wegovy pill, unapproved peptides, peptide testing, GLP-1 regulation</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/fda-approves-once-weekly-insulin-children-type-2-diabetes</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-03</news:publication_date>
      <news:title><![CDATA[FDA Approves First Once-Weekly Insulin for Children With Type 2 Diabetes]]></news:title>
      <news:keywords>insulin icodec, once-weekly insulin, pediatric type 2 diabetes, FDA approval, Awiqli, peptide therapeutics, GLP-1</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/nine-in-ten-eligible-teens-received-neither-glp1-nor-surgery</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-03</news:publication_date>
      <news:title><![CDATA[Nine in Ten Eligible Teens Received Neither Weight-Loss Drug Nor Surgery, Study Finds]]></news:title>
      <news:keywords>adolescent obesity, GLP-1 access, bariatric surgery adolescents, JAMA Pediatrics, semaglutide adolescents, pediatric obesity treatment, insurance coverage GLP-1</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/fda-interim-peptide-compounding-policy-white-house-review</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-02</news:publication_date>
      <news:title><![CDATA[FDA Peptide Compounding Policy Reaches White House Review as Safety Debate Sharpens]]></news:title>
      <news:keywords>FDA peptide policy, peptide compounding, 503A bulks list, BPC-157, TB-500, OIRA review, peptide regulation 2026, compounded peptides</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/malaysia-19-raids-retatrutide-ozempic-rm405170</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-02</news:publication_date>
      <news:title><![CDATA[Malaysia Tabulates 19 Raids on Unregistered GLP-1 Sales Worth RM405,170]]></news:title>
      <news:keywords>retatrutide, Malaysia Health Ministry, unregistered GLP-1, Ozempic seizure, peptide enforcement, TOBaTS, semaglutide regulation</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/thailand-suvarnabhumi-8900-glp1-pens-seized</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-02</news:publication_date>
      <news:title><![CDATA[Thailand Seizes 8,900 Unregistered GLP-1 Pens at Suvarnabhumi Airport]]></news:title>
      <news:keywords>Thailand GLP-1 seizure, Suvarnabhumi customs, weight-loss injection pens, semaglutide smuggling, peptide import enforcement, liraglutide</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/uk-border-seizures-retatrutide-10000-doses</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-02</news:publication_date>
      <news:title><![CDATA[10,000 Seized Doses: Britain's Border Problem Is Now Retatrutide]]></news:title>
      <news:keywords>retatrutide, UK border seizures, black market weight loss jabs, MHRA, grey market peptides, peptide testing, GLP-1 enforcement, counterfeit semaglutide</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/counsel-health-glp1-membership-300-year-medication-risk</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-02</news:publication_date>
      <news:title><![CDATA[A $300-a-Year GLP-1 Membership Is Cheap. The Drug Is Where the Risk Lives.]]></news:title>
      <news:keywords>GLP-1 telehealth, Counsel Health, LillyDirect, compounded semaglutide, tirzepatide, peptide testing, FDA warning letters, weight loss medication cost</news:keywords>
    </news:news>
  </url>
</urlset>